About Transgene

Transgene SA, a biopharmaceutical company, engages in the discovery and development of gene-based therapeutic vaccines and immunotherapy products for the treatment of cancer and infectious diseases. The company’s activities include all product development stages, including research, production of clinical batches, and conducting clinical trials. The company has a partnership agreement with Roche for subsequent development of one of its products. The company’s products are designed to restore the immune system’s ability to fight infectious diseases and cancer by eliminating abnormal or infected cells. They elicit new responses where conventional treatments are often only partially effective. Product Development Programs Primary Cutaneous Lymphoma Immunotherapy: TG1042 (Ad-IFN) This immunotherapy product is intended for the treatment of relapsed cutaneous B-cell lymphoma (CBCL). Precancerous Cervical Lesions Active Immunotherapy: TG4001/R3484 (MVA-HPV-IL2) This product targets human papillomavirus type 16 (HPV 16), which is a high-risk factor in the development of precancerous cervical neoplasia and subsequently cervical cancer. Hepatitis C Virus Active Immunotherapy: TG4040 (MVA-HCV) This product is intended to treat patients suffering from chronic hepatitis C. TG4023 (MVA-FCU1) TG4023 is intended to increase the efficacy of chemotherapy on solid tumors accessible via intra-tumoral injections. The indications for this product are liver metastasis and hepatocellular carcinoma. TG4023 uses the viral vector MVA, which contains the sequence coding FCU1 gene. The target market of TG4023 is the treatment of cancerous liver lesions. History Transgene SA was founded in 1979.